THE EXPERIENCE AND RESULTS OF CYTOREDUCTIVE SURGERY AND HIPEC USED IN ADVANCED OVARIAN CANCER
Abstract
The research object was life quality of patients with ovarian cancer after complex treatment. Nowadays cytoreductive surgery and HIPEC is the mainstay of management of advanced stages ovarian cancer.
Description of the problem: study was conducted to assess the effectiveness of combined treatment in IIIA-IIIC ovarian cancer, its impact on quality of life.
Main scientific results: 37 patients of main group (CRS + HIPEC) were compared with 25 patients of control group (surgery + systemic chemotherapy). The quality of life was assessed with Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Comparative analysis of quality of life 6 months after treatment completion did not show significant statistical difference. Combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer, is tolerated better and has less systemic toxicities than systemic chemotherapy.
The area of practical use of research results: hyperthermic intraperitoneal chemotherapy is performed for patients suffering from malignant tumors of the abdominal cavity, including metastatic colon cancer, ovarian cancer, stomach cancer, pseudomyxoma, mesothelioma, rhabdomyosarcoma, and some other types of oncology.
Innovative technological product: combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer.
Scope of application of an innovative technological product: HIPEC is an innovative treatment option for advanced cancer that has spread to the abdominal cavity (carcinomatosis) and has not gone beyond it.
Downloads
References
Bulletin of National Cancer Registry of Ukraine (2019). Kyiv, 21. Available at: http://www.ncru.inf.ua/publications/BULL_21/index_e.htm
Global Cancer Observatory. Available at: https://gco.iarc.fr/
Cotte, E., Glehen, O., Mohamed, F., Lamy, F., Falandry, C., Golfier, F., Gilly, F. N. (2007). Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients. World Journal of Surgery, 31 (9), 1813–1820. doi: http://doi.org/10.1007/s00268-007-9146-8
Parson, E. N., Lentz, S., Russell, G., Shen, P., Levine, E. A., Stewart, J. H. (2011). Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. The American Journal of Surgery, 202 (4), 481–486. doi: http://doi.org/10.1016/j.amjsurg.2011.02.004
Di Giorgio, A., Naticchioni, E., Biacchi, D., Sibio, S., Accarpio, F., Rocco, M. et. al. (2008). Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 113 (2), 315–325. doi: http://doi.org/10.1002/cncr.23553
Bakrin, N., Classe, J. M., Pomel, C., Gouy, S., Chene, G., Glehen, O. (2014). Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Journal of Visceral Surgery, 151 (5), 347–353. doi: http://doi.org/10.1016/j.jviscsurg.2014.07.005
Onda, T., Kobayashi, H., Nakanishi, T., Hatae, M., Iwasaka, T., Konishi, I. et. al. (2009). Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecologic Oncology, 113 (1), 57–62. doi: http://doi.org/10.1016/j.ygyno.2008.12.027
Di Giorgio, A., Naticchioni, E., Biacchi, D., Sibio, S., Accarpio, F., Rocco, M. et. al. (2008). Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 113 (2), 315–325. doi: http://doi.org/10.1002/cncr.23553
Chua, T. C., Yan, T. D., Saxena, A., Morris, D. L. (2019). Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Annals of Surgery, 249 (6), 900–907. doi: http://doi.org/10.1097/sla.0b013e3181a45d86
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., Montz, F. J. (2002). Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. Journal of Clinical Oncology, 20 (5), 1248–1259. doi: http://doi.org/10.1200/jco.2002.20.5.1248
Copyright (c) 2020 Oleksandr Bondar, Andriy Rybin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
